Will "no blood" kill Jehovah Witnesses?

A 46-year-old Indonesian woman presented with signs and symptoms suggestive of an ovarian tumour and was advised to have surgery with exploratory laparotomy and removal of the mass. She agreed but refused blood transfusion any time in the course of her treatment or procedure, as she was a Jehovah Witness. As there was a high risk of intraoperative haemorrhage, steps were taken to reduce any consequent complications due to the surgery. The ethical conflict is between respecting patient autonomy and compromising standards of care, arising from the refusal of a standard therapy. The latest developments in the blood transfusion doctrine policy for the Jehovah Witnesses are also discussed in this case study.

Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?

We determined the hemostatic and fibrinolytic status in 60 patients with ovarian cancer and benign ovarian cysts. Hypercoagulation, increased platelets, and enhanced fibrinolysis were seen in patients with preoperative ovarian cancer compared to patients with benign ovarian cysts. Enhanced thrombin generation, evidenced by increased F1+2 and decreased antithrombin III (ATIII) levels with further enhanced fibrinolysis by elevated D-dimer, was seen in advanced cancer. Ten ovarian cancer patients died within 13 months after diagnosis and another died at 24 months, all from advanced stage of cancer, except one from stage IC cancer who died at 11 months. The survival rates from the disease at 13 months and 24 months were 66.7% and 45%, respectively. Most of the patients had gone through the complete course of chemotherapy, and those patients still alive have been disease free between 13 and 42 months. No statistical relationships for the hemostatic parameters studied in ovarian cancer patients could be found between those who died and those still living 13 and 24 months after diagnosis, except for ATIII and D-dimer levels. Elevated D-dimer levels were associated with those who died within 13 and 24 months from the disease, and the decreased ATIII levels only reached statistical significance by 24 months. It could be suggested that these two parameters might be useful as systemic prognostic markers in survival outcome from the disease for the first 24 months in advanced ovarian cancer, in addition to the known correlation with the International Federation of Gynecology and Obstetrics stage.

A preliminary study of the immunohistochemical detection of a novel tumour marker, 22-1-1 antigen, in gynaecological cancer specimens.

A novel tumour associated antigen, 22-1-1, has been recently described in association with a cervical adenocarcinoma cell line. The aims of this paper were to study the tissue distribution of this antigen in sections of gynaecological cancer specimens and to compare it with negative controls. Six cases of cervical cancers, 5 cases of endometrial cancers, 4 cases of ovarian cancers and 5 cases each of normal endometrium and cervix were studied. Immunohistochemical staining using streptoavidin-biotin methodology was used for each tumour specimen. This revealed positive staining for the 22-1-1 antigen in 5 out of 6 cases of cervical cancer, 3 out of 5 cases of endometrial cancers, and all 4 cases of ovarian mucinous cystadenocarcinomas. Importantly, the antigen was expressed in the cytoplasm, cell membrane and glandular lumen of adenocarcinoma cells. The 22-1-1 antigen was not detected in normal uterine tissues except in uterine cervix, in which its expression was observed at low levels. This study shows that the 22-1-1 antigen was expressed in cancer cells derived from the uterus, cervix and the ovary and may be a potential tumour marker in the management of gynaecological cancer patients.

The classification of gestational trophoblastic disease: a critical review.

Gestational trophoblastic disease defines a group of conditions which arises from the fetal chorion. Two of the most important advances in the management of gestational trophoblastic disease have been the standardisation of terminology, and the concept of risk assignment based on classification or staging systems which allows rationalisation of treatment. Gestational trophoblastic disease is unique as the prognosis is dependent not only on the anatomic extent but also the presence of prognostic factors. A staging system similar to that used for other cancers does not apply to this disease because in most cases diagnosis is bases not on histology but on clinical or biochemical parameters. Metastatic spread to distant organs can occur early, even in the absence of disease in the uterus or pelvis. Staging in gestational trophoblastic disease must include prognostic factors in addition to anatomic extent of disease. Broadly there are two categories of classification in current use. The first is based on the usual staging system as in other cancers, with four stages of disease, but at the same time prognostic factors are incorporated. This has the important advantages of simplicity and uniformity with other staging systems. However the main pitfall is that no recommendations are made for treatment. The other broad category consists of risk tables, based on anatomic spread as well as prognostic factors. Here patients are assigned varying risk scores, with guidelines for multiagent chemotherapy at the outset in high-risk patients to minimise drug resistant disease. The ideal system would be one which has four stages of disease, so that comparison is easier, with recommendations for combination chemotherapy beyond a certain stage of disease.

The classification of gestational trophoblastic disease: a critical review.

Gestational trophoblastic disease defines a group of conditions which arises from the fetal chorion. Two of the most important advances in the management of gestational trophoblastic disease have been the standardisation of terminology, and the concept of risk assignment based on classification or staging systems which allows rationalisation of treatment. Gestational trophoblastic disease is unique as the prognosis is dependent not only on the anatomic extent but also the presence of prognostic factors. A staging system similar to that used for other cancers does not apply to this disease because in most cases diagnosis is bases not on histology but on clinical or biochemical parameters. Metastatic spread to distant organs can occur early, even in the absence of disease in the uterus or pelvis. Staging in gestational trophoblastic disease must include prognostic factors in addition to anatomic extent of disease. Broadly there are two categories of classification in current use. The first is based on the usual staging system as in other cancers, with four stages of disease, but at the same time prognostic factors are incorporated. This has the important advantages of simplicity and uniformity with other staging systems. However the main pitfall is that no recommendations are made for treatment. The other broad category consists of risk tables, based on anatomic spread as well as prognostic factors. Here patients are assigned varying risk scores, with guidelines for multiagent chemotherapy at the outset in high-risk patients to minimise drug resistant disease. The ideal system would be one which has four stages of disease, so that comparison is easier, with recommendations for combination chemotherapy beyond a certain stage of disease.

A series of ovarian clear cell and endometrioid carcinoma and their association with endometriosis.

AIM: To present our department's experience with clear cell carcinoma and endometrioid carcinoma of the ovary, paying particular attention to their relationship with endometriosis and concomitant endometrial pathology. METHOD: Retrospective review of case records. RESULTS: From July 1986 to March 1995, 11 patients with clear cell carcinoma and 20 patients with endometrioid carcinoma of the ovary were treated. Of the patients with clear cell carcinoma, five (45%) had associated endometriosis. One patient (9%) also had endometrial adenomatous hyperplasia. Of the 20 cases of ovarian endometrioid carcinoma, four (20%) had endometriosis present during histopathological examination. Six patients (30%) had concomitant endometrial pathology (five cases of endometrial carcinoma and one with adenomatous hyperplasia). CONCLUSION: Our series shows that the clear cell ovarian carcinoma may often be associated with endometriosis, more so than the endometrioid type of ovarian carcinoma. However, the patient with ovarian endometrioid carcinoma may also harbour a concurrent endometrial pathology.

Sexual behaviour and prevalence of HIV antibodies in transsexuals.

OBJECTIVE: To present data on the social characteristics, sexual behaviour and prevalence of HIV antibodies in 277 transsexuals. MATERIAL AND METHODS: One hundred fifty-four male and 123 female transsexuals requesting surgical gender reassignment at the National University Hospital, Singapore were interviewed using a standard questionnaire. Blood samples were also taken at booking and prior to surgery and tested for HIV antibodies using a commercial enzyme immunoassay. RESULTS: The mean ages of the male and female transsexuals were 26.3 and 28.3 years respectively. The majority of the transsexuals were Singaporean Chinese and had at least a secondary school education. None of the female and 14 (9%) of the male transsexuals were engaged in prostitution. Significantly more female (48%) than male (10.4%) transsexuals were sexually inactive. The sexual behaviour and practices of the transsexuals are also discussed. CONCLUSIONS: Significantly more male transsexuals compared to the female transsexuals, were sexually active, had earlier sexual contact, engaged more often in anal intercourse, and had 7 or more sexual partners. However, none of our transsexuals were positive for HIV antibodies.

Mild cervical atypia: a management dilemma.

This study examined 117 patients with mild cervical atypia or atypical squamous cells of uncertain significance; it was found that 25% had histologically proven CIN lesions by colposcopically-directed punch biopsy or cone biopsy. 18% were found to have at least CIN 2 lesions and there was 1 case of invasive cancer. These data strongly support the recommendation of early colposcopic referral in patients with mild cervical atypia.

Current approach to the management of urinary stress incontinence.

The plethora of treatment modalities available for the treatment of female urinary stress incontinence reflects the uncertainty in the pathophysiology of this condition and the mechanism of cure. No single treatment method is suitable for all patients. For best results, many factors must be considered before choosing the treatment method most suited to the particular patient. This review examines the various treatment options available and attempts to set out criteria for choice of treatment. The role of conservative treatment has been deliberately highlighted especially for young and well motivated women with mild to moderate urinary stress incontinence before surgical treatment is used. The role and limitations of well established surgical procedures like Burch colposuspension and urethroplasty and the more recently introduced procedures like collagen implants, laparoscopic colposuspension and the role of artificial urinary sphincter are also examined.

Papillary serous carcinoma of the peritoneum.

OBJECTIVE: To describe the clinical features of papillary serous carcinoma of the peritoneum followed by a short review of the literature. METHODS: From January 1986 to May 1994, six patients with papillary serous carcinoma of the peritoneum were treated at our institution. Their presenting features, sites of disease at the time of staging laparotomy, subsequent treatment and follow-up were reviewed. RESULTS: The mean age was 53.3 years (range 46-59). The most common presenting features were abdominal pain, distention and the presence of ascites. Common sites of disease at the time of laparotomy were the peritoneal and subdiaphragmatic surfaces, omentum, serosa of bowel and superficial involvement of the ovaries. Patients were treated with cytoreductive surgery and platinum-based chemotherapy. CONCLUSION: Although experience is scant and more data is needed, for the time being, management for primary peritoneal carcinoma is as for ovarian cancer.

Current views on the management of trophoblastic tumors.

Gestational trophoblastic disease has been recognized as a form of abnormal pregnancy as early as 1600 AD, and choriocarcinoma was the first cancer to be cured with chemotherapy even in the presence of distant and widespread metastases. Important advances in the past include the standardization of terminology, the concept of assignment of risk and the use of staging systems, the centralization of care and the establishment of regional registries, and of course the development of the radioimmunoassay for the beta subunit of human chorionic gonadotropin. The current views on the management of this disease recognizes the need for a multidisciplinary approach, with chemotherapy remaining at the forefront but also utilizing newer diagnostic techniques when necessary, and keeping in mind the crucial role that surgery can play especially in resistant cases. At the same time, the importance of basics such as careful follow up after evacuation of a hydatidiform mole cannot be overemphasized. There will be a continual refinement of the chemotherapy regimes used, and the aim is to achieve a similar level of response with decreased toxicity to the patient.

Early vulval cancer: the place of conservative management.

There is a trend towards conservative surgery for early vulval cancer, which is increasingly being diagnosed in younger women. In this series there were 21 patients who had lesions which had invaded to a depth of 3 mm or less. Nine patients were treated by wide local excision without any form of lymphadenectomy, and eight patients had wide local excision with ipsilateral groin dissection. In the remaining four patients, radical surgery was carried out, consisting of radical vulvectomy and bilateral lymphadenectomy. None of the 12 patients who had some form of lymphadenectomy was shown to have nodal involvement. None of the patients suffered from local recurrence or recurrence in the groin nodes. No patient died from vulval cancer, and all but one of the patients are still alive with a mean follow-up period of 54.8 months. Though there is as yet no universal agreement on the criteria for early vulval cancer, with superficial invasion there is a place for individualized treatment, when patients will benefit from less than radical surgery.

Reconstruction of the abdominal wall with a latissimus dorsi musculocutaneous flap: a case of a massive abdominal wall metastasis from a cervical cancer requiring palliative resection.

A 49-year-old woman presented with a huge abdominal mass. At laparotomy, a 36-cm diameter semisolid, semicystic mass from the abdominal wall was removed. The peritoneal defect was covered by a mesh and a free latissimus dorsi myocutaneous flap. Histology showed a poorly differentiated squamous cell carcinoma consistent with metastatic tumor from a cervical primary. Surgery has a finite palliative role to extirpate a tumor mass of this size if reconstruction and some form of closure can be achieved.

Induction of labour in nulliparas with poor cervical score: oxytocin or prostaglandin vaginal pessaries?

In a previous study nulliparas with poor cervical score (less than 5 out of 10) had a 43.5% Caesarean section (CS) rate of which 55% were for failed induction when labour was induced by artificial rupture of membranes and oxytocin infusion. In this study induction of labour by 2 doses of 3 mg prostaglandin E2 (PGE2) vaginal pessaries, 4 hours apart, and if necessary by artificial rupture of membranes and oxytocin infusion 24 hours later, resulted in a CS rate of 23.7% of which 38.9% were for failed induction. The latter regimen resulted in a significantly lower CS rate compared with labour induced by oxytocin infusion and rupture of membranes without the use of prostaglandins (p less than 0.001). In the prostaglandin group 53.3% were established in labour within 24 hours of inserting the pessary and in these patients the CS rate was 18.5%. In those who did not start labour and needed rupture of membranes and oxytocin infusion 24 hours after the first pessary, 34 (47.9%) had a good cervical score (greater than or equal to 6 out of 10) and 37 (52.1%) had a poor cervical score (less than or equal to 5 out of 10) at the time of amniotomy. The CS rates in these groups were 8.8% and 48.6% respectively (p less than 0.001). In nulliparas with poor cervical score induction is better performed with vaginal prostaglandin pessaries in order to reduce the high CS rate associated with artificial rupture of membranes and oxytocin infusion.

A comparison between fibreoptic and catheter-tip bridge strain gauge transducers for measurement of intrauterine pressure in labour.

A new fibreoptic pressure transducer was used to measure uterine activity in labour, and the results were compared with those obtained with the catheter-tip bridge strain gauge transducer. Readings were obtained from 8 patients in spontaneous labour, and a total of 565 contractions were analysed. When all contractions were analysed the coefficient of variation ranged from 11.24 to 42.74. In 2 patients with vast difference in pressure readings one of the catheters had slipped into the lower uterine segment, when these 2 cases were not considered the coefficient of variation ranged from 11.24 to 21.18. Even in the others there were transient periods lasting 5 to 15 minutes when the pressure difference was greater than 10 mmHg between the 2 catheters. When they were excluded from analysis, along with the 2 cases where one of the catheters was displaced, the coefficient of variation ranged from 9.30 to 16.05. The fibreoptic pressure transducer appears to be a safe, convenient and fairly accurate means of assessing uterine activity. But one must be aware that a catheter giving low readings compared with the initial period soon after insertion may be due to displacement of the transducer tip to the uterine lower segment.